FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study. PMID 40185210 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Preventing pulmonary complications after laparoscopic colorectal surgery: a lung-protective protocol vs. standard care: A randomised controlled trial. PMID 40159954 · Eur J Anaesthesiol · 2025-Sep-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial. PMID 41647992 · ESMO Gastrointest Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Ascorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial. PMID 41574117 · CHEST Crit Care · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial. PMID 41164606 · J Pharm Bioallied Sci · 2025-Sep The record describes a randomized trial in oncology with a drug intervention and primary time-to-event endpoints (PFS, OS). However, the abstract does not explicitly state the trial phase (e.g., Phase III, Phase II/III). Per adjudication rules, phase cannot be inferred. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the record ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Conventional partial pancreatoduodenectomy versus an uncinate first, extended partial pancreatoduodenectomy approach for the resection of pancreatic head cancer: the randomized, controlled PancER trial. PMID 41143201 · Innov Surg Sci · 2025-Sep 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib. PMID 41071292 · Ann Hematol · 2025-Sep The report is from a Phase III oncology RCT with drug intervention, but the specific analysis presented is a secondary analysis of quality-of-life data, not a report of a primary or key secondary time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria for a primary result report of a time-to-event endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. PMID 41054436 · EClinicalMedicine · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial. PMID 41025990 · Radiology · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Colorectal Cancer and Advanced Adenoma after Single CT Colonography or Biennial FIT Screening in the SAVE Randomized Controlled Trial. PMID 41025989 · Radiology · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Photodynamic Therapy for Peripheral Lung Cancer]. PMID 40998354 · Kyobu Geka · 2025-Sep The study is a randomized, multicenter trial in human oncology (NSCLC) with a primary time-to-event endpoint (PFS) and Kaplan-Meier analysis, making it potentially eligible. However, the intervention is Photodynamic Therapy (PDT), which is a device/light-based treatment, not a drug-containing intervention. The explicit phase is not stated in the metadata, and cannot be inferred from the drug name (as per instructions). Therefore, it does not meet the 'drug intervention' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Cardioprotection on the Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy. PMID 40965835 · Echocardiography · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy plus surgery in advanced ovarian cancer patients. PMID 40925342 · J Int Med Res · 2025-Sep The study is an oncology randomized trial with human subjects and reports primary time-to-event efficacy results (OS, PFS). However, the intervention (HIPEC) is not a systemic drug-containing intervention as required by the inclusion criteria; it is a locoregional/intraoperative procedure. The phase (Phase III/IIIb or II/III) is not explicitly established in the provided metadata. Therefore, it is excluded due to the absence of a qualifying drug intervention, making it ineligible for the specific cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint-Based Drop-The-Losers Design. PMID 40911375 · Stat Med · 2025-Sep The record describes a methodological study evaluating a 'drop-the-losers' adaptive design strategy for dose selection in oncology, including simulations and a lung cancer trial design example. While it mentions Phase II/III contexts and randomized elements, it does not present results from a specific Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The abstract focuses on multiplicity control, design evaluation, and software, not on reporting trial efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies. PMID 40910999 · Expert Opin Biol Ther · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor. PMID 40908570 · Cancer Med · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial. PMID 40907518 · Lancet Oncol · 2025-Sep The trial is a Phase 3 randomized oncology study with drug interventions, but the primary endpoint is chronic toxicity, not a time-to-event efficacy endpoint. No time-to-event efficacy results (OS, PFS, DFS, etc.) or associated Kaplan-Meier/HR data are reported in the abstract. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. PMID 40907514 · Lancet Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality assurance and reporting for FLASH clinical trials: The experience of the FEATHER trial. PMID 40904039 · Med Phys · 2025-Sep The record describes a protocol and methodology paper for a quality assurance program in a randomized phase II/III trial conducted in domestic animals, not a human trial. It does not report any time-to-event efficacy results or involve a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. PMID 40896880 · ESMO Open · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer. PMID 40893054 · JCO Precis Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial. PMID 40865372 · Lung Cancer · 2025-Sep This is a randomized trial for a surgical technique (non-invasive localization) in lung cancer, not a drug intervention. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility of non-routine abdominal drainage for minimally invasive liver surgery: study protocol for a multicenter randomized controlled clinical trial. PMID 40860204 · Int J Surg Protoc · 2025-Sep 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Artificial Intelligence-Based Multimodal Prediction of Postoperative Adjuvant Immunotherapy Benefit in Urothelial Carcinoma: Results From the Phase III, Multicenter, Randomized, IMvigor010 Trial. PMID 40859961 · MedComm (2020) · 2025-Sep This is a secondary, post-hoc biomarker analysis from the primary IMvigor010 trial, focused on developing an AI-based predictive score. The abstract does not present primary time-to-event efficacy results (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) from the trial itself, but rather discusses the predictive performance of the UAIscore in stratifying patients. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The Effect of Preoperative Magnetic Resonance Imaging on Long-term Oncological Outcomes Following Radical Prostatectomy-A 12-year Follow-up of a Randomized Controlled Trial. PMID 40823001 · Eur Urol Open Sci · 2025-Sep 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial. PMID 40775469 · Surg Endosc · 2025-Sep The study is a randomized, prospective trial comparing two endoscopic surgical techniques (cap-aspiration lumpectomy vs. endoscopic submucosal dissection) for small gastric submucosal tumors. It is not a Phase III/IIIb or Phase II/III trial, does not involve a drug-containing intervention, and reports surgical/technical outcomes (resection time, cost, complications) without a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial. PMID 40773982 · Oral Oncol · 2025-Sep The record is a pilot randomized controlled trial for a lymphedema and fibrosis self-management program in head and neck cancer survivors. It is oncology and human, and it is randomized. However, it fails multiple key eligibility criteria: it is a pilot study (not definitive Phase III/IIIb or Phase II/III), it does not involve a drug intervention, and it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC) receiving chemoradiotherapy (CRT). PMID 40763415 · Lung Cancer · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. PMID 40752515 · Lancet Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Description of a cruciferous vegetable intervention trial to test the efficacy of a maintenance component to reduce bladder cancer recurrence and progression. PMID 40750073 · Contemp Clin Trials · 2025-Sep The record is a protocol for a randomized controlled trial testing a dietary intervention for bladder cancer. It is not a report of results, does not involve a drug intervention, and does not assess a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Short-term outcomes of nonintubated and intubated video-assisted thoracoscopic surgery in management of malignant pleural effusion. PMID 40739892 · Asian Cardiovasc Thorac Ann · 2025-Sep The record describes a randomized comparison of two procedural techniques (nonintubated vs intubated VATS) for managing malignant pleural effusion. It does not involve a drug-containing intervention (the intervention is surgical technique with anesthesia type). The primary endpoints are short-term postoperative outcomes (pain scores, dyspnea, radiographic findings), not time-to-event efficacy endpoints like OS, PFS, DFS, etc., and no Kaplan-Meier survival curves or hazard ratios are reported. Therefore, it fails two key eligibility criteria: drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enhanced recovery after surgery programs versus conventional rehabilitation for patients undergoing thoracoscopic radical resection of lung cancer in local regional hospitals: a prospective randomized controlled trial. PMID 40696211 · Surg Endosc · 2025-Sep Eligible as a randomized, human, oncology trial with primary results, but excluded because the intervention is non-drug-only (comparing rehabilitation programs, not a drug) and no time-to-event endpoint is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The 2018 World Cancer Research Fund/American Institute for Cancer Research Score and Cancer Risk: results from the diabetes prevention program outcomes study. PMID 40675492 · Am J Clin Nutr · 2025-Sep The study is a secondary analysis of a randomized trial (lifestyle vs. metformin vs. placebo for diabetes prevention) examining the association between a lifestyle score and cancer incidence. It meets oncology, human, randomized, and time-to-event criteria, but fails the drug intervention and phase3_or_definitive criteria because the analyzed exposure is a lifestyle score, not a drug, and the oncology analysis is not a definitive trial of a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation. PMID 40668865 · Am J Respir Crit Care Med · 2025-Sep The study analyzes fluid resuscitation strategies in sepsis, a non-oncology condition, and does not involve a drug intervention or meet oncology-specific criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of the IMProving Adherence to medications for breast Cancer and cardiovascular disease equiTably (IMPACT) randomized clinical trial. PMID 40653311 · Contemp Clin Trials · 2025-Sep The record is a protocol for a randomized trial in breast cancer patients, but it is not a report of results. The stated outcomes (medication adherence at 28/52 weeks, CVD risk factor control) are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial. PMID 40652952 · Lancet Respir Med · 2025-Sep The record describes a randomized, double-blind, placebo-controlled trial of adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in immunocompromised, HIV-negative patients. It is not an oncology trial focused on a malignant neoplasm. Furthermore, the primary efficacy endpoint is 28-day mortality, which is a binary, fixed-time-point outcome, not a time-to-event endpoint (e.g., OS, PFS) amenable to Kaplan-Meier analysis or hazard ratio reporting. The trial phase is not specified in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial. PMID 40651596 · Radiother Oncol · 2025-Sep Excluded because it is a quality-of-life analysis without a primary/key secondary time-to-event efficacy endpoint and lacks a drug-containing intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial. PMID 40643775 · Breast Cancer Res Treat · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial. PMID 40639764 · Radiother Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results. PMID 40632415 · Gastric Cancer · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications. PMID 40624990 · J Oral Pathol Med · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial. PMID 40618901 · Radiother Oncol · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial. PMID 40615729 · Nat Cancer · 2025-Sep This is an oncology trial with human participants and a time-to-event endpoint, but it is a single-arm, non-randomized study without a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial. PMID 40615712 · Br J Cancer · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Psychological Interventions and Sleep Improvement for Patients with Gastric Cancer: Effects on Immune Function, Inflammation, and Tumor Progression-A Randomized Controlled Trial. PMID 40603815 · Ann Surg Oncol · 2025-Sep The study is a randomized oncology trial with time-to-event endpoints, but the intervention is primarily non-drug (psychological and sleep program with melatonin supplement), and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Author's reply: "Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial". PMID 40582956 · Dig Liver Dis · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Optimized post-discharge care in patients with frailty after colon cancer surgery (project ERAS® 3.0): A protocol for a randomized controlled trial. PMID 40554849 · J Geriatr Oncol · 2025-Sep 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nutritional outcomes and impact of malnutrition in a randomised comparison between standard and prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer. PMID 40550184 · Eur J Surg Oncol · 2025-Sep The record is a substudy within a randomized trial comparing timing of surgery after neoadjuvant chemoradiotherapy. It reports OS as a time-to-event endpoint. However, it is not eligible because the intervention being studied is not a drug; it is the timing of surgery. The main trial compares standard vs. prolonged time to surgery, not a drug regimen. Therefore, the requirement for a drug-containing intervention is not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. PMID 40542959 · Adv Ther · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Diabetes Mellitus and Lung Cancer Screening Outcomes in the National Lung Screening Trial. PMID 40540649 · Ann Am Thorac Soc · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |